PL4073025T3 - Sole metali i ich zastosowania - Google Patents

Sole metali i ich zastosowania

Info

Publication number
PL4073025T3
PL4073025T3 PL20897654.8T PL20897654T PL4073025T3 PL 4073025 T3 PL4073025 T3 PL 4073025T3 PL 20897654 T PL20897654 T PL 20897654T PL 4073025 T3 PL4073025 T3 PL 4073025T3
Authority
PL
Poland
Prior art keywords
applications
metal salts
salts
metal
Prior art date
Application number
PL20897654.8T
Other languages
English (en)
Inventor
Stephen Wald
Eduardo J. Martinez
Samuel STRATFORD
Amanda BUIST
Joseph Benson
Jonathan LOUGHREY
Original Assignee
Inspirna, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inspirna, Inc. filed Critical Inspirna, Inc.
Publication of PL4073025T3 publication Critical patent/PL4073025T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL20897654.8T 2019-12-13 2020-12-11 Sole metali i ich zastosowania PL4073025T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962947968P 2019-12-13 2019-12-13
PCT/US2020/064456 WO2021119397A1 (en) 2019-12-13 2020-12-11 Metal salts and uses thereof

Publications (1)

Publication Number Publication Date
PL4073025T3 true PL4073025T3 (pl) 2024-09-16

Family

ID=76320705

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20897654.8T PL4073025T3 (pl) 2019-12-13 2020-12-11 Sole metali i ich zastosowania

Country Status (14)

Country Link
US (4) US11174220B2 (pl)
EP (1) EP4073025B1 (pl)
JP (1) JP7689964B2 (pl)
CN (1) CN114728875A (pl)
AU (1) AU2020401286A1 (pl)
CA (1) CA3161274A1 (pl)
ES (1) ES2982346T3 (pl)
HU (1) HUE067466T2 (pl)
MX (1) MX2022007164A (pl)
PL (1) PL4073025T3 (pl)
RS (1) RS65646B1 (pl)
TW (1) TWI888447B (pl)
WO (1) WO2021119397A1 (pl)
ZA (1) ZA202206588B (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020345791A1 (en) * 2019-09-11 2022-03-31 Inspirna, Inc. Methods of treating cancer
JP7689964B2 (ja) 2019-12-13 2025-06-09 インスピルナ，インコーポレーテッド 金属塩及びその使用

Family Cites Families (204)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1317860A (pl) * 1961-03-20 1963-05-08
DD150456A5 (de) 1979-03-01 1981-09-02 Ciba Geigy Ag Verfahren zur herstellung von derivaten des 3-amino-1,2-propandiols
DE2951400A1 (de) 1979-12-20 1981-07-02 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von n,n'-diarylaethylendiaminen oder n, n',n''-triaryldiaethylen-triaminen
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
DK196688A (da) * 1987-04-28 1988-10-29 Fujisawa Pharmaceutical Co Bicykliske forbindelser og fremgangsmaade til fremstilling deraf
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5324731A (en) 1989-02-14 1994-06-28 Amira, Inc. Method of inhibiting transformation of cells in which purine metabolic enzyme activity is elevated
US5676978A (en) 1989-02-14 1997-10-14 Amira, Inc. Methods of inhibiting undesirable cell growth using a combination of a cyclocreatine compound and a hyperplastic inhibitory agent
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5215882A (en) 1989-11-30 1993-06-01 Ortho Diagnostic Systems, Inc. Method of immobilizing nucleic acid on a solid surface for use in nucleic acid hybridization assays
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
CA2111503A1 (en) 1993-12-15 1995-06-16 Mcgill University Apolipoprotein e polymorphism and alzheimer's disease
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
DE69621507T2 (de) 1995-03-28 2003-01-09 Japan Science And Technology Corp., Kawaguchi Verfahren zur molekularen Indexierung von Genen unter Verwendung von Restriktionsenzymen
US5843974A (en) 1995-06-06 1998-12-01 Eli Lilly And Company Methods of inhibiting melanoma using Benzothiophenes as cytotoxic agents per se
US5958342A (en) 1996-05-17 1999-09-28 Incyte Pharmaceuticals, Inc. Jet droplet device
US6060240A (en) 1996-12-13 2000-05-09 Arcaris, Inc. Methods for measuring relative amounts of nucleic acids in a complex mixture and retrieval of specific sequences therefrom
US5945289A (en) 1996-12-20 1999-08-31 Lehrer; Steven Method for detecting prostate cancer by apolipoprotein E (Apo-E) genotyping
US6090556A (en) 1997-04-07 2000-07-18 Japan Science & Technology Corporation Method for quantitatively determining the expression of a gene
US5994076A (en) 1997-05-21 1999-11-30 Clontech Laboratories, Inc. Methods of assaying differential expression
US20030153541A1 (en) 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
ES2276481T3 (es) 1997-12-12 2007-06-16 The University Of Western Ontario Peptido apoep1.b novedoso, composiciones y sus usos.
US6004755A (en) 1998-04-07 1999-12-21 Incyte Pharmaceuticals, Inc. Quantitative microarray hybridizaton assays
US6048695A (en) 1998-05-04 2000-04-11 Baylor College Of Medicine Chemically modified nucleic acids and methods for coupling nucleic acids to solid support
US6087112A (en) 1998-12-30 2000-07-11 Oligos Etc. Inc. Arrays with modified oligonucleotide and polynucleotide compositions
US6906069B1 (en) 1999-01-08 2005-06-14 Amgen Inc. LXR modulators
US6316503B1 (en) 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
US8257750B2 (en) 1999-04-30 2012-09-04 Kibow Biotech, Inc. Calcium carbonate compositions for preventing or treating hyperphosphatemia
JP2002543216A (ja) 1999-04-30 2002-12-17 アーチ ディベロップメント コーポレイション ステロイド誘導体
WO2001066534A2 (en) 2000-03-09 2001-09-13 Abbott Laboratories Cyclic and bicyclic diamino histamine-3 receptor antagonists
AU2001280576A1 (en) 2000-07-18 2002-01-30 Uab Research Foundation Tissue-specific self-inactivating gene therapy vector
WO2002013594A1 (en) 2000-08-17 2002-02-21 Northland Seed & Grain Corp. Method for minimizing contamination of crops and products derived therefrom
WO2002020737A2 (en) 2000-09-07 2002-03-14 Vanderbilt University Genome engineering by cell-permeable dna site-specific recombinases
DE60107449T2 (de) 2000-09-18 2005-12-08 Glaxo Group Ltd., Greenford Substituierte aminopropoxyarylderivate als lxr agonisten
KR20030070150A (ko) * 2001-01-31 2003-08-27 화이자 프로덕츠 인크. Ｐｄｅ4 이소자임 억제제로서 유용한 에테르 유도체
WO2002062302A2 (en) 2001-02-08 2002-08-15 The University Of Chicago Steroidal derivatives
JP4309661B2 (ja) 2001-05-03 2009-08-05 ザ ユニバーシティー オブ シカゴ 肝臓ｘ受容体
US6908934B2 (en) 2001-06-11 2005-06-21 Merck & Co., Inc. Therapeutic compounds for treating dyslipidemic conditions
JP2003033179A (ja) 2001-07-05 2003-02-04 Asahi Kasei Corp 可逆的遺伝子導入ベクター
AU2002336433A1 (en) 2001-10-08 2003-04-22 Eli Lilly And Company Tricyclic compounds useful for modulating lxr
JP2005513026A (ja) 2001-11-15 2005-05-12 インサイト サン ディエゴ インコーポレイテッド 高コレステロール血症、異脂肪血症および他の代謝障害；癌、および他の疾患を治療するｎ−置換複素環
US20050014807A1 (en) 2001-11-21 2005-01-20 Adams Alan D Therapeutic compounds for treating dyslipidemic conditions
US7998986B2 (en) 2001-12-21 2011-08-16 Exelixis Patent Company Llc Modulators of LXR
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
EP1465882B1 (en) 2001-12-21 2011-08-24 X-Ceptor Therapeutics, Inc. Hetrocyclic modulators of nuclear receptors
BR0215258A (pt) 2001-12-21 2004-12-07 Pharmacia Corp Moduladores de receptor x de fìgado de tioéter aromático
AU2003220521A1 (en) 2002-03-27 2003-10-13 Smithkline Beecham Corporation Methods of treatment with lxr modulators
JP2005521721A (ja) * 2002-03-27 2005-07-21 スミスクライン・ビーチャム・コーポレイション 酸およびエステル化合物ならびにその使用方法
EP1497270A4 (en) 2002-03-27 2006-01-04 Smithkline Beecham Corp AMID COMPOUNDS AND METHOD FOR THEIR USE
AU2003226094A1 (en) 2002-03-27 2003-10-13 Smithkline Beecham Corporation Compounds and methods
AU2003222667A1 (en) 2002-04-23 2003-11-10 Chugai Seiyaku Kabushiki Kaisha 1,3-thiazoles as lxr modulators in the treatment of cardiovascular diseases
WO2003090732A1 (en) 2002-04-23 2003-11-06 Chugai Seiyaku Kabushiki Kaisha Lxr modulators for the treatment of cardiovascular diseases
WO2003090869A1 (en) 2002-04-23 2003-11-06 Chugai Seiyaku Kabushiki Kaisha Lxr modulators
MXPA04011691A (es) 2002-05-24 2005-09-12 Pharmacia Corp Moduladores del receptor x anilino hepaticos.
US6822120B2 (en) 2002-05-24 2004-11-23 Pharmacia Corporation Sulfone liver X-receptor modulators
WO2004009091A1 (en) 2002-06-17 2004-01-29 Glaxo Group Limited Purine derivatives as liver x receptor agonists
WO2003106435A1 (en) 2002-06-18 2003-12-24 Sankyo Company, Limited Fused-ring pyrimidin-4(3h)-one derivatives, processes for the preparation and uses thereof
EP1552010B1 (en) 2002-07-19 2010-06-09 Althea Technologies, Inc. Strategies for gene expression analysis
AU2003256655A1 (en) 2002-07-25 2004-02-16 Merck And Co., Inc. Therapeutic compounds for treating dyslipidemic conditions
DK1529116T3 (da) 2002-08-07 2009-11-09 Novartis Ag Fremgangsmåde til forudsigelse af respons på behandling med rivastigmin baseret på ApoE-genotypen hos demenspatienter
EP1407774A1 (en) 2002-09-10 2004-04-14 LION Bioscience AG 2-Amino-4-quinazolinones as LXR nuclear receptor binding compounds
US20040110947A1 (en) 2002-09-17 2004-06-10 Pharmacia Corporation Aromatic liver X-receptor modulators
WO2004058717A1 (en) 2002-12-20 2004-07-15 X-Ceptor Therapeutics, Inc. Isoquinolinone derivatives and their use as therapeutic agents
WO2004072042A2 (en) 2003-02-12 2004-08-26 Carex S.A. Quinoline derivative and their use for modulation of lxr activity
WO2004072041A1 (en) 2003-02-12 2004-08-26 Care X S.A. Tetrahydroquinolines as agonists of liver- x receptors
WO2004072046A2 (en) 2003-02-12 2004-08-26 Carex S.A. Quinoline derivatives and their use for modulation of lxr activity
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
WO2004078939A2 (en) 2003-03-03 2004-09-16 University Of Massachusetts REGULATION OF Mdm2 FUNCTION
GB0316237D0 (en) 2003-07-11 2003-08-13 Astrazeneca Ab Therapeutic agents
GB0316232D0 (en) 2003-07-11 2003-08-13 Astrazeneca Ab Therapeutic agents
US20050130919A1 (en) 2003-07-18 2005-06-16 University Of Massachusetts Regulatable promoters for synthesis of small hairpin RNA
US20060264424A1 (en) 2003-08-12 2006-11-23 Tularik Inc Arylsulfonamidobenzylic compounds
HRP20110009T1 (hr) 2003-09-03 2011-03-31 Kowa Co. Spoj kojim se aktivira ppar i farmaceutski pripravak koji ga sadrži
JP2006193426A (ja) 2003-09-05 2006-07-27 Sankyo Co Ltd 置換された縮環ピリミジン−４（３ｈ）−オン化合物
AU2004283053A1 (en) 2003-10-20 2005-05-06 Nsgene A/S In vivo gene therapy of Parkinson's Disease
US20050113419A1 (en) 2003-10-31 2005-05-26 Huang Shaei Y. Therapeutic compounds for treating dyslipidemic conditions
JP2007516258A (ja) 2003-12-12 2007-06-21 ワイス 心臓血管の疾患治療に有用なキノリン誘導体
FR2865736B1 (fr) 2004-02-02 2006-07-14 Synt Em Inhibiteurs de l'angiogenese, compositions les contenant et leur utilisation pour le traitement des maladies liees a une deregulation de l'angiogenese
EP1713799A4 (en) 2004-02-11 2010-07-07 Irm Llc COMPOUNDS AND COMPOSITIONS AS MODULATORS OF LXR
BRPI0507626A (pt) 2004-02-11 2007-07-03 Irm Llc compostos e composiçoes como moduladores de lxr
JP4705630B2 (ja) 2004-03-26 2011-06-22 エフ．ホフマン−ラ ロシュ アーゲー テトラヒドロカルバゾール及び誘導体
MXPA06012683A (es) 2004-05-03 2007-01-16 Hoffmann La Roche Derivados de indolilo como moduladores de receptor x del higado.
WO2005112620A2 (en) 2004-05-18 2005-12-01 Massachusetts Institute Of Technology A cre-lox based method for conditional rna interference
WO2005113499A1 (ja) 2004-05-20 2005-12-01 Sankyo Company, Limited インドール化合物
MXPA06014807A (es) 2004-06-28 2007-02-12 Hoffmann La Roche Nuevos derivados de hexafluorisopropanol.
TW200606133A (en) 2004-06-30 2006-02-16 Sankyo Co Substituted benzene compounds
JP5575357B2 (ja) 2004-07-02 2014-08-20 第一三共株式会社 組織因子産生抑制剤
DE602005017895D1 (de) 2004-07-07 2010-01-07 Merck & Co Inc Pyrazolamid-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren
GT200500208A (es) 2004-08-03 2006-03-02 Indazoles ùtiles para tratar enfermedades cardiovasculares
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060178398A1 (en) 2004-09-16 2006-08-10 Adams Alan D Therapeutic compounds for treating dyslipidemic conditions
PL1802566T3 (pl) 2004-10-01 2009-05-29 Hoffmann La Roche Podstawione heksafluoroizopropanolem pochodne eteru
US7923573B2 (en) 2004-10-27 2011-04-12 Daiichi Sankyo Company, Limited Benzene compound having 2 or more substituents
RU2382029C2 (ru) 2004-12-22 2010-02-20 Ф.Хоффманн-Ля Рош Аг Новые производные циклогексана
MX2007008370A (es) 2005-01-10 2007-08-21 Astrazeneca Ab Derivados de 1,1-dioxidos de isotiazol-3 (2h) -ona como moduladores del receptor del higado x.
SE0500058D0 (sv) 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 5
SE0500056D0 (sv) 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 4
WO2006073364A1 (en) 2005-01-10 2006-07-13 Astrazeneca Ab Derivatives of isothiazol-3 (2h)-thione 1,1-dioxides as liver x receptor modulators
SE0500055D0 (sv) 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
JP2006232703A (ja) 2005-02-23 2006-09-07 Dai Ichi Seiyaku Co Ltd フェニルエーテル誘導体及びそれを用いた医薬
RU2007131400A (ru) 2005-03-01 2009-04-10 Вайет (Us) Соединения циннолина и их применение в качестве модуляторов х-рецепторов печени
US8318760B2 (en) 2005-03-21 2012-11-27 Merck Sharp & Dohme Corp. Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use
WO2006109633A1 (ja) 2005-04-07 2006-10-19 Daiichi Sankyo Company, Limited 置換インドール化合物
KR101363278B1 (ko) 2005-06-27 2014-02-21 엑셀리시스 페이턴트 컴퍼니 엘엘씨 이미다졸계 ｌｘｒ 변조제
WO2007022563A1 (en) 2005-08-24 2007-03-01 Graham Scott Package with bitter taste aversive agent for infant deterrant
NZ567140A (en) 2005-10-07 2011-09-30 Exelixis Inc Azetidines as MEK inhibitors for the treatment of proliferative diseases
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
WO2007050271A2 (en) 2005-10-25 2007-05-03 Wyeth 5-lipoxygenase modulators
US20090062260A1 (en) 2005-11-14 2009-03-05 Irm Llc Compounds and compositions as lxr modulators
WO2007081335A1 (en) 2006-01-12 2007-07-19 Merck & Co., Inc. Therapeutic compounds for treating dyslipidemic conditions
US20100279918A1 (en) 2006-03-20 2010-11-04 Burnham Institute For Medical Research Chimeric Constructs Between Cancer-Homing Peptides and Cell-Penetrating Peptides Coupled to Anticancer Drugs and/or Diagnostic Agent/Agents
WO2007110755A1 (en) * 2006-03-27 2007-10-04 Medical Therapies Limited Prophylaxis or treatment of cardiovascular inflammation
WO2008011071A2 (en) 2006-07-19 2008-01-24 The Regents Of The University Of California Interactions of hedgehog and liver x receptor signaling pathways
US20080085879A1 (en) 2006-08-31 2008-04-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of treating estrogen-responsive conditions by orphan nuclear receptor activation
TW200825054A (en) 2006-10-18 2008-06-16 Wyeth Corp Quinoline compounds
US8324367B2 (en) 2006-11-03 2012-12-04 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
EP1925621A1 (en) * 2006-11-27 2008-05-28 Novartis AG Crystalline forms of zoledronic acid
US8168666B2 (en) 2006-11-30 2012-05-01 Kowa Company, Ltd. Substituted carbinol compound
EP2121621B1 (en) 2006-12-08 2014-05-07 Exelixis Patent Company LLC Lxr and fxr modulators
JP2008179562A (ja) 2007-01-24 2008-08-07 Kowa Co Ｌｘｒアゴニスト
US8993628B2 (en) 2007-02-23 2015-03-31 City Of Hope Synthetic ligands selective for LXRβ over LXRα, identification and methods of use thereof
US20100273816A1 (en) 2007-05-18 2010-10-28 Ronald Charles Bernotas Quinazoline Compounds
CA2691673A1 (en) 2007-06-29 2009-01-08 Avi Biopharma, Inc. Tissue specific peptide conjugates and methods
KR101171507B1 (ko) 2007-08-13 2012-08-07 에프. 호프만-라 로슈 아게 신규 피페라진 아마이드 유도체
TW200922582A (en) 2007-08-20 2009-06-01 Organon Nv N-benzyl, N'-arylcarbonylpiperazine derivatives
US8039493B2 (en) 2007-09-27 2011-10-18 Hoffmann-La Roche Inc. Biaryl sulfonamide derivatives
DK2205737T3 (da) 2007-10-04 2013-05-21 Santaris Pharma As Mikromirer
US7902147B2 (en) 2007-11-05 2011-03-08 Duke University Chronic lymphocytic leukemia prognosis and treatment
WO2009060198A1 (en) 2007-11-09 2009-05-14 Peregrine Pharmaceuticals, Inc. Anti-vegf antibody compositions and methods
US8236753B2 (en) 2007-12-10 2012-08-07 The Brigham And Women's Hospital, Inc. RAP variants for drug delivery and methods of use thereof
EP2071509A1 (en) 2007-12-13 2009-06-17 Gemalto SA Method and apparatus to mark a document using a combination between guilloches and watermarking, method and apparatus to read previous combination
WO2009086123A1 (en) 2007-12-21 2009-07-09 Wyeth Imidazo [1,2-a] pyridine compounds
EP2235020A1 (en) 2007-12-21 2010-10-06 Wyeth LLC Pyrazolo [1,5-a] pyrimidine compounds
AU2008345696A1 (en) 2007-12-21 2009-07-09 Wyeth Llc Benzimidazole compounds
CA2710458A1 (en) 2007-12-21 2009-07-09 Wyeth Llc Imidazo [1,2-b] pyridazine compounds as modulators of liver x receptors
US7919509B2 (en) 2008-02-29 2011-04-05 Kowa Company, Ltd. 2-oxochromene derivatives
US7951822B2 (en) 2008-03-31 2011-05-31 Kowa Company, Ltd. 1,3-dihydroisobenzofuran derivatives
US8008306B2 (en) 2008-04-30 2011-08-30 Kowa Company, Ltd. Quinoline compounds
TW201006816A (en) 2008-05-15 2010-02-16 Organon Nv Hexafluoroisopropanol derivatives
AU2009255357A1 (en) 2008-05-29 2009-12-10 Bristol-Myers Squibb Company Methods for predicting patient response to modulation of the co-stimulatory pathway
WO2009144961A1 (ja) 2008-05-29 2009-12-03 興和株式会社 環状リンカーを有する置換カルビノール化合物
US8063088B2 (en) 2008-06-11 2011-11-22 Hoffmann-La Roche Inc. Imidazolidine derivatives
CN102137680A (zh) 2008-07-01 2011-07-27 克格诺西有限公司 用apoe肽治疗癌症的方法
TW201022230A (en) 2008-08-28 2010-06-16 Organon Nv 1-(4-ureidobenzoyl)piperazine derivatives
US8613367B2 (en) 2008-08-29 2013-12-24 Saint-Gobain Performance Plastics Corporation Sealing assembly and method of making such assembly
FR2935380B1 (fr) 2008-08-29 2010-09-10 Galderma Res & Dev Nouveaux composes hexafluoro-2-biphenyl-isopropanol, modulateurs des recepteurs de type lxrs, leur procede de preparation et leur application comme medicaments en medecine humaine ou veterinaire ainsi qu'en cosmetique.
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
CN102361857B (zh) 2008-09-26 2015-09-16 默沙东公司 可用作抗糖尿病剂的环状苯并咪唑衍生物
WO2010059627A1 (en) 2008-11-19 2010-05-27 Wyeth Llc Polar quinazolines as liver x receptors ( lxrs ) modulators
US20120156216A1 (en) 2009-03-02 2012-06-21 Youngman Oh Methods and Compositions for Treatment of Tumor Metastasis
CN102438991B (zh) 2009-04-29 2015-08-26 兴和株式会社 具有杂环连接基的甲醇化合物
MY153958A (en) 2009-05-28 2015-04-30 Exelixis Patent Co Llc Lxr modulators
JP2013500986A (ja) 2009-07-29 2013-01-10 ザ・ユニバーシティ・オブ・シカゴ 肝臓ｘ受容体アゴニスト
KR101636958B1 (ko) * 2009-09-11 2016-07-06 주식회사 대웅제약 우루소데옥시콜린산-합성하이드로탈사이트-유드라짓 혼성체, 이를 함유하는 약학 조성물 및 그 제조방법
TWI513695B (zh) 2009-10-27 2015-12-21 Merck Sharp & Dohme （１，１，１，３，３，３－六氟－２－羥基丙－２－基）苯基衍生物
EP2499142B1 (en) 2009-11-09 2016-09-21 Advinus Therapeutics Limited Substituted fused pyrimidine compounds, its preparation and uses thereof
CN102884047B (zh) 2009-12-04 2015-11-25 日产化学工业株式会社 2-吡啶酮化合物
WO2011103175A2 (en) 2010-02-16 2011-08-25 The Regents Of The University Of California Oxysterols that activate liver x receptor signaling and inhibit hedgehog signaling
WO2011115892A1 (en) 2010-03-15 2011-09-22 Griffin Patrick R Modulators of the retinoic acid receptor-related orphan receptors
US9421218B2 (en) 2010-04-13 2016-08-23 New York University Compositions and methods for treatment of melanoma
JP5851400B2 (ja) 2010-06-16 2016-02-03 Ｌｓｉｐファンド運営合同会社 大腸腫瘍の検出方法
MX2012014801A (es) 2010-07-08 2013-01-29 Wyeth Llc Esteres de quinolina nuevos utiles para el tratamento de transtornos cutaneos.
EP2474617A1 (en) 2011-01-11 2012-07-11 InteRNA Technologies BV Mir for treating neo-angiogenesis
US20130004481A1 (en) 2011-01-12 2013-01-03 Boehringer Ingelheim International Gmbh Anticancer therapy
US20120231457A1 (en) 2011-03-10 2012-09-13 Nikolaos Tezapsidis Compositions and methods for assessing a genetic risk of developing late-onset alzheimer's disease (load)
US9629910B2 (en) 2011-03-22 2017-04-25 The Brigham And Women's Hospital, Inc. Use of Th9 cells and IL-9 for the treatment of melanoma
TW201242953A (en) 2011-03-25 2012-11-01 Bristol Myers Squibb Co Imidazole prodrug LXR modulators
JP2014526506A (ja) 2011-09-15 2014-10-06 ノバルティス アーゲー 中等度肝障害患者の癌治療における４−アミノ−５−フルオロ−３−［６−（４−メチルピペラジン−１−イル）−１ｈ−ベンゾイミダゾール−２−イル］−１ｈ−キノリン−２−オンの使用
WO2013043569A1 (en) 2011-09-20 2013-03-28 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
CN103054844B (zh) 2011-10-18 2014-04-30 中国科学院武汉病毒研究所 一种gw3965在制备治疗或预防丙型肝炎药物中的应用
CN103958541A (zh) 2011-10-18 2014-07-30 国家医疗保健研究所 5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇的酸加成盐
WO2013076257A1 (en) 2011-11-24 2013-05-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Process for the preparation of sterol derivatives
SG11201405378VA (en) 2012-03-02 2014-09-26 Anayaderm Inc Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions
ES2607113T3 (es) 2012-03-16 2017-03-29 Vitae Pharmaceuticals, Inc. Moduladores de los receptores X del hígado
SG11201405328SA (en) 2012-03-16 2014-11-27 Vitae Pharmaceuticals Inc Liver x receptor modulators
WO2014028461A2 (en) 2012-08-13 2014-02-20 The Rockefeller University Treatment and diagnosis of melanoma
JP6442475B2 (ja) 2013-03-15 2018-12-19 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｌｘｒ調節因子
JP6066860B2 (ja) 2013-08-05 2017-01-25 株式会社クボタ 草刈機
WO2015065505A1 (en) 2013-10-29 2015-05-07 Duke University Use of cyp27a1 inhibitors, statin, or lxr antagonists alone or in combination with conventional therapy for the treatment of breast cancer
AU2015204572B2 (en) 2014-01-10 2020-07-30 Inspirna, Inc. LXR agonists and uses thereof
AP2016009261A0 (en) 2014-02-07 2016-06-30 Global Blood Therapeutics Inc Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
JP6626085B2 (ja) 2014-07-15 2019-12-25 ザ・ジョンズ・ホプキンス・ユニバーシティー 骨髄由来抑制細胞の抑制及び免疫チェックポイント阻害の方法
WO2016100619A2 (en) 2014-12-17 2016-06-23 Rgenix, Inc. Treatment and diagnosis of cancer
US20160271149A1 (en) 2015-03-16 2016-09-22 Epinova Therapeutics Corp. Therapeutic compounds that suppress protein arginine methyltransferase activity for reducing tumor cell proliferation
US20170056352A1 (en) 2015-08-25 2017-03-02 Rgenix, Inc. PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
JP7725185B2 (ja) 2015-10-06 2025-08-19 アレクトル エルエルシー 抗ｔｒｅｍ２抗体及びその使用方法
US11058700B2 (en) 2015-10-28 2021-07-13 City Of Hope Macrocyclic lactones and uses thereof as modulators of purinergic receptors
AU2017207291B2 (en) 2016-01-11 2023-06-15 The Rockefeller University Methods for the treatment of myeloid derived suppressor cells related disorders
KR102412690B1 (ko) 2016-02-05 2022-06-23 다이호야쿠힌고교 가부시키가이샤 중증 신장 기능 장애를 갖는 암 환자에 대한 치료 방법
EP3430171B1 (en) 2016-03-16 2022-03-02 The Regents of the University of California Detection and treatment of anti-pd-1 therapy resistant metastatic melanomas
WO2017181163A2 (en) 2016-04-16 2017-10-19 Oncocyte Corporation Methods and compositions for detection and diagnosis of breast cancer
MX2019002946A (es) 2016-09-14 2019-09-26 Abbvie Biotherapeutics Inc Anticuerpos anti-pd-1 y sus usos.
WO2018160178A1 (en) 2017-03-01 2018-09-07 Rgenix, Inc. Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof
ES2975417T3 (es) * 2017-03-03 2024-07-05 Inspirna Inc Formulaciones con estabilidad mejorada
EP3713575A4 (en) * 2017-11-21 2021-08-25 Rgenix, Inc. POLYMORPHS AND THEIR USES
CN109251974A (zh) 2018-02-14 2019-01-22 重庆京因生物科技有限责任公司 基于poct模式的apoe2和apoe4基因型快速检测试剂盒
WO2020176846A2 (en) 2019-02-28 2020-09-03 The Rockefeller University Apoe genotyping in cancer prognostics and treatment
CN113906149A (zh) 2019-03-29 2022-01-07 百欧恩泰美国公司 持久临床获益的癌症生物标志物
JP7689964B2 (ja) 2019-12-13 2025-06-09 インスピルナ，インコーポレーテッド 金属塩及びその使用

Also Published As

Publication number Publication date
ZA202206588B (en) 2023-11-29
EP4073025A4 (en) 2023-07-05
EP4073025A1 (en) 2022-10-19
CA3161274A1 (en) 2021-06-17
EP4073025B1 (en) 2024-03-27
US20230095288A1 (en) 2023-03-30
MX2022007164A (es) 2022-09-12
US20210179539A1 (en) 2021-06-17
ES2982346T3 (es) 2024-10-15
US20240174595A1 (en) 2024-05-30
JP7689964B2 (ja) 2025-06-09
HUE067466T2 (hu) 2024-10-28
TW202136188A (zh) 2021-10-01
JP2023509845A (ja) 2023-03-10
WO2021119397A1 (en) 2021-06-17
US11878956B2 (en) 2024-01-23
AU2020401286A1 (en) 2022-06-23
US20220041541A1 (en) 2022-02-10
WO2021119397A9 (en) 2021-10-14
CN114728875A (zh) 2022-07-08
EP4073025C0 (en) 2024-03-27
TWI888447B (zh) 2025-07-01
US11459292B2 (en) 2022-10-04
US11174220B2 (en) 2021-11-16
RS65646B1 (sr) 2024-07-31
US12258303B2 (en) 2025-03-25
NZ789129A (en) 2025-03-28

Similar Documents

Publication Publication Date Title
IL283639A (en) Kif18a inhibitors
DK3999506T3 (da) Parp1-hæmmere
EP3843714C0 (en) CD73 INHIBITORS
EP4007756C0 (en) KIF18A INHIBITORS
DK4043466T3 (da) PRC2-inhibitorer
DK4051688T3 (da) Cd73-hæmmere
IL281514A (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
DK3956322T3 (da) Jak1-selektiv kinaseinhibitor
EP4077580C0 (en) Refrigerant
EP3861264C0 (en) FRIDGE
EP4053412A4 (en) Compressor
EP3978468A4 (en) CONNECTION AND COMPOSITION
EP3940230A4 (en) COMPRESSOR
EP4027073C0 (en) REFRIGERATION DEVICE
EP4083249A4 (en) ALLOY
EP3976797A4 (en) ANTI-CRISPR INHIBITORS
DK3932909T3 (da) Benzoindazolonforbindelse og mellemprodukt heraf
EP3913768A4 (en) Compressor
EP3794362C0 (en) METAL DETECTOR
EP4027017A4 (en) COMPRESSOR
EP3601449A4 (en) SYNERGISTIC METAL POLYCARBOXYLATE CORROSION INHIBITORS
EP3933198C0 (en) COMPRESSOR
EP4073025A4 (en) METAL SALTS AND USES THEREOF
EP3683077C0 (de) Kühlvorrichtung
CA189017S (fr) Basketball